Hypera SA
BOVESPA:HYPE3

Watchlist Manager
Hypera SA Logo
Hypera SA
BOVESPA:HYPE3
Watchlist
Price: 20.55 BRL 1.88% Market Closed
Market Cap: 13B BRL

Hypera SA
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hypera SA
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Hypera SA
BOVESPA:HYPE3
Operating Income
R$1.7B
CAGR 3-Years
-3%
CAGR 5-Years
30%
CAGR 10-Years
7%
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
Operating Income
R$866.9m
CAGR 3-Years
83%
CAGR 5-Years
77%
CAGR 10-Years
N/A

Hypera SA
Glance View

Market Cap
13B BRL
Industry
Pharmaceuticals

Hypera S.A., a leading force in the Brazilian pharmaceuticals market, has carved a niche by catering to a wide spectrum of health needs through a diverse portfolio. Originally established under the name Hypermarcas, the company took root with the ambition of becoming a pharmaceutical powerhouse in Brazil. This vision was set in motion through strategic organic growth and a series of savvy acquisitions, which helped consolidate its offerings across over-the-counter (OTC) medications, branded prescriptions, dermo-cosmetics, and generics. Each of these segments represents a cog in the machine that drives Hypera’s profitability, with its robust pipeline of drug innovations and strong brand presence ensuring a steady flow of revenue. What truly sets Hypera apart is its ability to harness the synergies between its diverse product lines and an extensive distribution network across Brazil. The company generates revenue not only by selling pharmaceuticals directly to consumers but also through collaborations with healthcare professionals and pharmacies, ensuring its products reach a vast market. Hypera’s commitment to research and development further fuels its growth engine, as it continuously seeks to introduce new drugs and treatments that meet the evolving healthcare demands. The company’s strategic focus on operational efficiency and cost management underpins its financial performance, while its strong brand recognition makes it a preferred choice among consumers and medical professionals alike in Brazil’s dynamic healthcare environment.

HYPE3 Intrinsic Value
40.36 BRL
Undervaluation 49%
Intrinsic Value
Price

See Also

What is Hypera SA's Operating Income?
Operating Income
1.7B BRL

Based on the financial report for Dec 31, 2024, Hypera SA's Operating Income amounts to 1.7B BRL.

What is Hypera SA's Operating Income growth rate?
Operating Income CAGR 10Y
7%

Over the last year, the Operating Income growth was -30%. The average annual Operating Income growth rates for Hypera SA have been -3% over the past three years , 30% over the past five years , and 7% over the past ten years .

Back to Top